客观的角膜染色检查也证实，和基线资料相比，两组都在早期就有明显改善，环孢霉素A组为-1.07，联合用药组为-1.39，至研究结束时，效果更明显（环孢霉素A组-1.27，环孢霉素A/酮咯酸组-1.74）两组6周时的差异有统计学意义。

　　Conclusion from study

　　研究结论

　　At the study conclusion, mean improvement in the ocular surface disease index (OSDI) score was also greater in the cyclosporine/ketorolac group compared with cyclosporine monotherapy (-23.85 versus -15.03, respectively), and there was a trend toward statistical significance for the difference. Schirmer test scores and tear break-up time values were also assessed and found to be improved during the study in both groups, but there was no statistically significant difference between groups in the changes from baseline at either 2 or 6 weeks, and no adverse events occurred with the use of ketorolac over the 6 weeks of the study.

　　研究结束时，眼表疾病指数（OSDI）评分也显示，环孢霉素A/酮咯酸组的效果好于单用环隐霉素A组（分别是-23.85和-15.03）。两组的Schirmer试验和泪膜破裂时间都有改善，但无论是2周，还是6周的检查中，两组在此方面并无明显差异。并且在6周的研究中，并未发现酮咯酸的副作用。

　　Clinicians may be hesitant to prescribe a topical NSAID in patients with significant dry eye disease based on previous reports of corneal complications,” Dr. Schechter said.” However, in this study, objectively and subjectively, ketorolac demonstrated favorable safety as an adjunct to cyclosporine in patients with existing ocular surface damage when used over a short period with regular physician monitoring.”

　　Dr. Schechter称：“曾有有关局部应用NSAID引起角膜并发症的报道，临床医生也许会因此不给患者使用这类药物。但在这项研究中，无论是客观检查，还是主观感觉，都证明在定期的随访下，眼表疾病患者应用环孢霉素A的同时短期加用酮咯酸很安全。”

上一页  [1] [2] [3]